Rational, computer-enabled peptide drug design: principles, methods, applications and future directions.
暂无分享,去创建一个
Jon Swanson | Alexander S. Bayden | Joseph Audie | David J Diller | Alexander S Bayden | Mark Jarosinski | D. Diller | M. Jarosinski | J. Audie | Jon Swanson
[1] H. K. Fung,et al. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. , 2012, Journal of medicinal chemistry.
[2] R. Dror,et al. Long-timescale molecular dynamics simulations of protein structure and function. , 2009, Current opinion in structural biology.
[3] Erkki Ruoslahti,et al. De novo design of a tumor-penetrating peptide. , 2013, Cancer research.
[4] Ri-Bo Huang,et al. Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design. , 2015, Medicinal chemistry (Shariqah (United Arab Emirates)).
[5] Rickey P Hicks,et al. A brief overview of antimicrobial peptides containing unnatural amino acids and ligand-based approaches for peptide ligands. , 2013, Current topics in medicinal chemistry.
[6] Belal Chaudhary,et al. Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases , 2015, Expert opinion on therapeutic targets.
[7] R. Béliveau,et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.
[8] Meng Wang,et al. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs. , 2014, Journal of medicinal chemistry.
[9] Nir London,et al. Rosetta FlexPepDock ab-initio: Simultaneous Folding, Docking and Refinement of Peptides onto Their Receptors , 2011, PloS one.
[10] Haiyan Jiang,et al. Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. , 2015, Molecular medicine reports.
[11] Erkki Ruoslahti,et al. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.
[12] Chen Jiang,et al. Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease , 2013, PloS one.
[13] Q. Du,et al. Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions , 2014, SAR and QSAR in environmental research.
[14] Premendu P. Mathur,et al. PepBind: A Comprehensive Database and Computational Tool for Analysis of Protein–peptide Interactions , 2013, Genom. Proteom. Bioinform..
[15] R. Roberts,et al. Serum Stable Natural Peptides Designed by mRNA Display , 2014, Scientific Reports.
[16] Elena B Pasquale,et al. EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity* , 2005, Journal of Biological Chemistry.
[17] Joshua A. Kritzer,et al. Peptide Bicycles that Inhibit the Grb2 SH2 Domain , 2012, Chembiochem : a European journal of chemical biology.
[18] John C Chaput,et al. Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. , 2009, Journal of the American Chemical Society.
[19] Spiros Liras,et al. Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. , 2015, European journal of medicinal chemistry.
[20] François Laviolette,et al. Machine Learning Assisted Design of Highly Active Peptides for Drug Discovery , 2015, PLoS Comput. Biol..
[21] Toru Okayama,et al. Synthesis and Structure−Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, Nα-Amidino-Tyr-d-Arg-Phe-MeβAla-OH (ADAMB) , 2002 .
[22] Hugo O. Villar,et al. Development of an Informatics Platform for Therapeutic Protein and Peptide Analytics , 2013, J. Chem. Inf. Model..
[23] Matthew P Jacobson,et al. Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. , 2015, Journal of medicinal chemistry.
[24] Siegfried S. F. Leung,et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. , 2015, Journal of the American Chemical Society.
[25] Christodoulos A. Floudas,et al. New Compstatin Peptides Containing N-Terminal Extensions and Non-Natural Amino Acids Exhibit Potent Complement Inhibition and Improved Solubility Characteristics , 2014, Journal of medicinal chemistry.
[26] Matthew P Jacobson,et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.
[27] Richard Svensson,et al. Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability. , 2013, Journal of medicinal chemistry.
[28] Matthew T. Weinstock,et al. Protease‐resistant peptide design—empowering nature's fragile warriors against HIV , 2012, Biopolymers.
[29] Matthew P. Jacobson,et al. Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.
[30] David J. Craik,et al. Molecular Grafting onto a Stable Framework Yields Novel Cyclic Peptides for the Treatment of Multiple Sclerosis , 2013, ACS chemical biology.
[31] Roderich D Süssmuth,et al. Conformational investigation of antibiotic proximicin by X-ray structure analysis and quantum studies suggest a stretched conformation of this type of γ-peptide. , 2013, Bioorganic & medicinal chemistry.
[32] Avraham Ben-Shimon,et al. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). , 2011, Journal of medicinal chemistry.
[33] Julio A Camarero,et al. Cyclotides, a promising molecular scaffold for peptide‐based therapeutics , 2010, Biopolymers.
[34] Hiroyuki Nishimori,et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. , 2011, The Journal of clinical investigation.
[35] David J Craik,et al. Cyclotides as grafting frameworks for protein engineering and drug design applications. , 2013, Biopolymers.
[36] Jürgen Bajorath,et al. High-resolution view of compound promiscuity , 2013, F1000Research.
[37] Erkki Ruoslahti,et al. Tumor-Penetrating Peptides , 2013, Front. Oncol..
[38] Christodoulos A. Floudas,et al. De Novo Peptide Design and Experimental Validation of Histone Methyltransferase Inhibitors , 2014, PloS one.
[39] Donna A Volpe,et al. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.
[40] Youhua Li,et al. A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. , 2013, Journal of medicinal chemistry.
[41] Yizhong Zhang,et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds , 2011, Nature chemical biology.
[42] Rossella Galati,et al. Increased Resistance of Peptides to Serum Proteases by Modification of their Amino Groups , 2003, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[43] Bernhard Y. Renard,et al. Docking small peptides remains a great challenge: an assessment using AutoDock Vina , 2015, Briefings Bioinform..
[44] Aleksander S Popel,et al. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. , 2011, Journal of medicinal chemistry.
[45] Martin S. Taylor,et al. Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. , 2008, Biophysical journal.
[46] C. Campañá,et al. Clinically Significant Drug Interactions with Cyclosporin An Update , 1996, Clinical pharmacokinetics.
[47] Alexandre M. J. J. Bonvin,et al. A Unified Conformational Selection and Induced Fit Approach to Protein-Peptide Docking , 2013, PloS one.
[48] Stephen W. Fesik,et al. Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A , 2014, Journal of medicinal chemistry.
[49] Haiou Li,et al. PaFlexPepDock: Parallel Ab-Initio Docking of Peptides onto Their Receptors with Full Flexibility Based on Rosetta , 2014, PloS one.
[50] Mingdong Huang,et al. Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs , 2011, Molecular Pharmacology.
[51] L. Usvyat,et al. Anaphylaxis and hypotension after administration of peginesatide. , 2014, The New England journal of medicine.
[52] Hans J. Vogel,et al. Serum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs , 2010, PloS one.
[53] François Stricher,et al. PepX: a structural database of non-redundant protein–peptide complexes , 2009, Nucleic Acids Res..
[54] Pierre Tufféry,et al. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides , 2012, Nucleic Acids Res..
[55] Erkki Ruoslahti,et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide , 2012, Oncogene.
[56] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[57] Clemencia Pinilla,et al. Identification of Tetrapeptides from a Mixture Based Positional Scanning Library That Can Restore nM Full Agonist Function of the L106P, I69T, I102S, A219V, C271Y, and C271R Human Melanocortin-4 Polymorphic Receptors (hMC4Rs) , 2014, Journal of medicinal chemistry.
[58] Gang Li,et al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma , 2015, Molecular medicine reports.
[59] Mateusz Kurcinski,et al. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site , 2015, Nucleic Acids Res..
[60] Hiroaki Suga,et al. Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies. , 2015, Current opinion in chemical biology.
[61] Vikas Nanda,et al. Empirical estimation of local dielectric constants: Toward atomistic design of collagen mimetic peptides , 2015, Biopolymers.
[62] C. Heinis,et al. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. , 2013, Protein engineering, design & selection : PEDS.
[63] N. Tsomaia. Peptide therapeutics: targeting the undruggable space. , 2015, European journal of medicinal chemistry.
[64] Pierre Tufféry,et al. PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces , 2014, Nucleic Acids Res..
[65] Haruki Nakamura,et al. Computer-aided antibody design , 2012, Protein engineering, design & selection : PEDS.
[66] Rahul Kumar,et al. TumorHoPe: A Database of Tumor Homing Peptides , 2012, PloS one.
[67] Minsuk Choi,et al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. , 2014, Cancer research.
[68] Erkki Ruoslahti,et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability , 2014, Nature Communications.
[69] Sylvia Van Dorpe,et al. Brainpeps: the blood–brain barrier peptide database , 2012, Brain Structure and Function.
[70] Bing Gu,et al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles , 2011, Journal of drug targeting.
[71] Thomas Kodadek,et al. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. , 2007, Chemistry & biology.
[72] Nir London,et al. In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2. , 2012, Biochemistry.
[73] Fan Yang,et al. Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel , 2015, Scientific Reports.
[74] Punit Upadhyaya,et al. Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonist. , 2013, Journal of the American Chemical Society.
[75] Nir London,et al. The structural basis of peptide-protein binding strategies. , 2010, Structure.
[76] D Altschuh,et al. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. , 1992, Science.
[77] Joost Schymkowitz,et al. Protein-peptide complex prediction through fragment interaction patterns. , 2013, Structure.
[78] Kuo-Chen Chou,et al. Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction. , 2007, Protein engineering, design & selection : PEDS.
[79] M. Wood,et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.
[80] J. Reichert,et al. Future directions for peptide therapeutics development. , 2013, Drug discovery today.
[81] T. Dix,et al. Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral Pain , 2013, The open medicinal chemistry journal.
[82] Joseph Audie,et al. Recent work in the development and application of protein-peptide docking. , 2012, Future medicinal chemistry.
[83] Avraham Ben-Shimon,et al. AnchorDock: Blind and Flexible Anchor-Driven Peptide Docking. , 2015, Structure.
[84] Ralf Bergmann,et al. Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight. , 2015, Journal of medicinal chemistry.
[85] Phillip Stafford,et al. Discovery of High-Affinity Protein Binding Ligands – Backwards , 2010, PloS one.
[86] R. Dror,et al. How Fast-Folding Proteins Fold , 2011, Science.
[87] Kerstin Schmidt,et al. A Rationally Engineered Anti-HIV Peptide Fusion Inhibitor with Greatly Reduced Immunogenicity , 2012, Antimicrobial Agents and Chemotherapy.
[88] E. Morgan,et al. Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.
[89] B. Davidson,et al. Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.
[90] Jianping Wang,et al. Influence of an unnatural amino acid side chain on the conformational dynamics of peptides. , 2012, Chemphyschem : a European journal of chemical physics and physical chemistry.
[91] Rhiju Das,et al. Four Small Puzzles That Rosetta Doesn't Solve , 2011, PloS one.
[92] L. Walensky,et al. Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.
[93] J. Tam,et al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. , 2012, Angewandte Chemie.
[94] Spiros Liras,et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.
[95] Roberto Improta,et al. Bond distances in polypeptide backbones depend on the local conformation. , 2015, Acta crystallographica. Section D, Biological crystallography.
[96] Derek J Richard,et al. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer , 2015, Molecular Cancer.
[97] Bruce Randall Donald,et al. Computational Design of a PDZ Domain Peptide Inhibitor that Rescues CFTR Activity , 2012, PLoS Comput. Biol..
[98] T. Hoffmann,et al. Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.
[99] Chengfei Yan,et al. Predicting peptide binding sites on protein surfaces by clustering chemical interactions , 2015, J. Comput. Chem..
[100] H. K. Fung,et al. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. , 2010, Biophysical journal.
[101] Zhimin Xiang,et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.
[102] Christodoulos A Floudas,et al. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a , 2014, European journal of pharmacology.
[103] Ora Schueler-Furman,et al. Rosetta FlexPepDock web server—high resolution modeling of peptide–protein interactions , 2011, Nucleic Acids Res..
[104] Jin Sun,et al. PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution. , 2014, Current drug metabolism.
[105] Michel Demeule,et al. Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.
[106] K. Chou,et al. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. , 2008, Current protein & peptide science.
[107] Hyo-Eon Jin,et al. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics , 2015, Expert opinion on therapeutic targets.
[108] Channa K. Hattotuwagama,et al. A Dataset of Experimental HLA-B*2705 Peptide Binding Affinities , 2014 .
[109] Pascal Tétreault,et al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. , 2014, The Journal of clinical investigation.
[110] Yizhong Zhang,et al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). , 2012, MedChemComm.
[111] Hongmin Li,et al. Modulation, Bioinformatic Screening, and Assessment of Small Molecular Peptides Targeting the Vascular Endothelial Growth Factor Receptor , 2014, Cell Biochemistry and Biophysics.
[112] Burak Erman,et al. VitAL: Viterbi Algorithm for de novo Peptide Design , 2010, PloS one.
[113] Ernst Schönbrunn,et al. Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.
[114] M. Walkinshaw,et al. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. , 1993, Journal of molecular biology.
[115] David J. Craik,et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients , 2014, Proceedings of the National Academy of Sciences.
[116] R. Doyle,et al. Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. , 2011, Journal of medicinal chemistry.
[117] Nathan Brown,et al. Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.
[118] Annick Thomas,et al. In silico predictions of 3D structures of linear and cyclic peptides with natural and non‐proteinogenic residues , 2012, Journal of peptide science : an official publication of the European Peptide Society.
[119] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[120] Erkki Ruoslahti,et al. Tumor-Penetrating iRGD Peptide Inhibits Metastasis , 2014, Molecular Cancer Therapeutics.
[121] Ryuichi Matsuno,et al. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. , 2004, Bioorganic & medicinal chemistry.
[122] Stefan Wallin,et al. Exploring Protein-Peptide Binding Specificity through Computational Peptide Screening , 2013, PLoS Comput. Biol..
[123] Tom C. Karagiannis,et al. Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy , 2014, The Journal of Membrane Biology.
[124] Hasup Lee,et al. GalaxyPepDock: a protein–peptide docking tool based on interaction similarity and energy optimization , 2015, Nucleic Acids Res..
[125] O. Chepurny,et al. Synthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1 , 2013, ChemMedChem.